Both lung histology and gene expression of α-SMA and collagen I evidenced that ATO+Cu2+ treatment can reduce pulmonary fibrosis with preservation of the pulmonary alveoli, and a decrease in cellular infiltrate and the accumulation of collagen. The gene discussed is ACTA1; the disease is pulmonary fibrosis.